SCSalut Colell

Salut Colell

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Salut Colell has a total of 65 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • CD70 overexpression at diagnosis predicts relapse and supports dual CD19-CD70 CAR T-cell therapy in follicular lymphoma

    by Ferran Araujo-Ayala, Maria Ros, Raluca Alexandru, Judith Mateos-Jaimez, Alba Rodriguez-Garcia, Marta Giménez-Alejandre, María Villalba-Esparza, Pablo Mozas, Guillem Colell, Salut Colell, et al.

    Although first-line immunotherapy achieves remission in most patients with follicular lymphoma (FL), improved biomarkers and therapeutic strategies are required to identify and manage those who relapse. We investigated the immune microenvironment at diagnosis in uniformly treated patients with FL with extended follow-up (>11 years), comparing patients with relapsed disease and those with relapse-free disease. Transcriptomic profiling revealed the enrichment of inflammatory response pathways in relapsed patients, including cytokine overexpression and upregulation of CD70, a molecule implicated in immune activation and inflammation. Multiplex immunofluorescence confirmed CD70 overexpression at diagnosis in tumor cells as well as in CD8+ and CD4+ T follicular helper cells, correlating with inferior progression-free survival. Functional studies demonstrated that CD70+ tumor cells were more proliferative and induced CD70 expression in T cells, suggesting a feed-forward loop sustaining immune activation. To target these cells and enhance current chimeric antigen receptor (CAR) T-cell approaches, we engineered dual CD19-CD70 CAR T cells by cotransducing the CD19 CAR T-cell product ARI-0001 with a CD27-based anti-CD70 CAR. Dual CAR T cells exhibited enhanced in vitro cytotoxicity against patient-derived spheroids of FL, diffuse large B-cell lymphoma, and mantle cell lymphoma. In FL xenograft models, dual CAR T-cell treatment achieved superior disease control compared to monotargeted CAR T cells, inducing complete tumor clearance in the spleen and bone marrow. Collectively, these findings provide a strong preclinical rationale for the clinical development of CD19-CD70 dual CAR T-cell therapy to improve outcomes in high-risk FL and potentially other B-cell non-Hodgkin lymphomas.


  • Open Access

    Context-dependent tonic signaling shapes the performance and manufacturability of a 4-1BB–based HER2 CAR-T cell therapy

    by Laura Angelats, Berta Marzal, Alba Rodriguez-Garcia, Marta Español-Rego, Teresa Lobo-Jarne, Maria Hernandez-Sanchez, Guim Cascalló, Salut Colell, Marta Giménez-Alejandre, Guillem Colell, et al.

    The development of clinically effective CAR-T cell therapies for solid tumors requires careful optimization of receptor design, functional fitness, and manufacturability. While advancing low-affinity HER2-targeting CAR-T cells toward clinical application, we found that the candidate with the strongest in vivo antitumor activity—comprising a CD8α hinge and transmembrane region and a 4-1BB co-stimulatory domain—exhibited measurable tonic signaling. This basal antigen-independent signaling, likely driven by high CAR surface expression, was associated with increased apoptosis and reduced ex vivo expansion under research-grade manufacturing conditions. Modification of the transmembrane domain reduced CAR surface expression but did not alleviate tonic signaling and instead impaired antitumor activity. By contrast, transient pharmacologic inhibition of CAR signaling with dasatinib rescued expansion and reduced apoptosis in small-scale research cultures. Notably, these tonic-signaling-associated defects were largely absent during large-scale, GMP-compliant manufacturing, which enabled robust CAR-T cell expansion without additional benefit from dasatinib supplementation. Together, these findings show that tonic signaling is not inherently detrimental to CAR-T cell performance and that its functional consequences are highly dependent on manufacturing context. Our study underscores the importance of evaluating CAR candidates within clinically relevant production platforms and supports the advancement of this 4-1BB–based HER2-specific CAR-T cell product toward clinical testing.


  • Open Access

    In vivo CRISPR-based screen identifies ZC3H12C as a mediator of CAR-T cell dysfunction in solid tumors

    by Paula Barbao, Alba Rodriguez-Garcia, Ariel Galindo-Albarrán, Marta Giménez-Alejandre, Pablo Clavero, Teresa Lobo-Jarne, Marta Botas, Guillem Colell, Joan Castellsagué, Guim Cascalló, et al.

    CAR-T cell therapy has shown limited efficacy in solid tumors, largely due to T cell dysfunction driven by chronic antigen exposure. To uncover mediators of this dysfunction, we developed an in vivo screening platform using an ovarian xenograft tumor model in which CD28-based CAR-T cells undergo exhaustion leading to tumor escape. Transcriptomic profiling of tumor-infiltrating CAR-T cells at different stages revealed dynamic upregulation of exhaustion-associated genes. We used this data to design a focused CRISPR/Cas9 library and performed an in vivo screen. We identified 14 significantly enriched candidate genes, among which ZC3H12C emerged as the top hit. Single-cell RNA and ATAC-seq confirmed ZC3H12C expression in CAR-T cells undergoing early exhaustion in vivo . ZC3H12C disruption enhanced CAR-T cell persistence and antitumor efficacy while reducing exhaustion, across both CD28- and 4-1BB-based CARs targeting distinct antigens. These results highlight ZC3H12C as a promising target to improve CAR-T therapy in solid tumors.


  • Open Access

    CAR affinity modulates the sensitivity of CAR-T cells to PD-1/PD-L1-mediated inhibition

    by Irene Andreu-Saumell, Alba Rodriguez-Garcia, Vanessa Mühlgrabner, Marta Gimenez-Alejandre, Berta Marzal, Joan Castellsagué, Fara Brasó-Maristany, Hugo Calderon, Laura Angelats, Salut Colell, et al.

    Chimeric antigen receptor (CAR)-T cell therapy for solid tumors faces significant hurdles, including T-cell inhibition mediated by the PD-1/PD-L1 axis. The effects of disrupting this pathway on T-cells are being actively explored and controversial outcomes have been reported. Here, we hypothesize that CAR-antigen affinity may be a key factor modulating T-cell susceptibility towards the PD-1/PD-L1 axis. We systematically interrogate CAR-T cells targeting HER2 with either low (LA) or high affinity (HA) in various preclinical models. Our results reveal an increased sensitivity of LA CAR-T cells to PD-L1-mediated inhibition when compared to their HA counterparts by using in vitro models of tumor cell lines and supported lipid bilayers modified to display varying PD-L1 densities. CRISPR/Cas9-mediated knockout (KO) of PD-1 enhances LA CAR-T cell cytokine secretion and polyfunctionality in vitro and antitumor effect in vivo and results in the downregulation of gene signatures related to T-cell exhaustion. By contrast, HA CAR-T cell features remain unaffected following PD-1 KO. This behavior holds true for CD28 and ICOS but not 4-1BB co-stimulated CAR-T cells, which are less sensitive to PD-L1 inhibition albeit targeting the antigen with LA. Our findings may inform CAR-T therapies involving disruption of PD-1/PD-L1 pathway tailored in particular for effective treatment of solid tumors.


  • Open Access

    CAR affinity modulates the sensitivity of CAR-T cells to PD-1/PD-L1-mediated inhibition

    by Sonia Guedan, Irene Andreu-Saumell, Alba Rodriguez-Garcia, Marta Gimenez-Alejandre, Joan Castellsagué, Vanessa Mühlgrabner, Fara Brasó-Maristany, Hugo Calderon, Berta Marzal, Salut Colell, et al.

    CAR-T cell therapy for solid tumors faces significant hurdles, including T-cell inhibition mediated by the PD-1/PD-L1 axis. The effects of disrupting this pathway on T-cells are being actively explored and controversial outcomes have been reported. Here, we hypothesize that CAR-antigen affinity may be a key factor modulating T-cell susceptibility towards the PD-1/PD-L1 axis. We systematically interrogated CAR-T cells targeting HER2 with either low (LA) or high affinity (HA) in various preclinical models. Our results revealed an increased sensitivity of LA CAR-T cells to PD-L1-mediated inhibition when compared to their HA counterparts by using in vitro models of tumor cell lines and supported lipid bilayers (SLB) modified to display varying PD-L1 densities. CRISPR/Cas9-mediated knockout (KO) of PD-1 enhanced LA CAR-T cell cytokine secretion and polyfunctionality in vitro and antitumor effect in vivo and resulted in downregulation of gene signatures related to T-cell exhaustion. By contrast, HA CAR-T cell features remained unaffected following PD-1 KO. This behavior held true for CD28 and ICOS but not 4-1BB co-stimulated CAR-T cells, which were less sensitive to PD-L1 inhibition. Our findings may inform CAR-T therapies involving disruption of PD-1/PD-L1 pathway tailored in particular for effective treatment of solid tumors.